Interleukin-2 and dendritic cells as adjuvants for surgical therapy of tumours associated with human papillomavirus type 16
Language English Country Netherlands Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
12547599
DOI
10.1016/s0264-410x(02)00537-6
PII: S0264410X02005376
Knihovny.cz E-resources
- MeSH
- Adjuvants, Immunologic administration & dosage MeSH
- Dendritic Cells immunology MeSH
- Tumor Virus Infections pathology surgery therapy MeSH
- Papillomavirus Infections pathology surgery therapy MeSH
- Interleukin-2 administration & dosage MeSH
- Combined Modality Therapy MeSH
- Mice, Inbred C57BL MeSH
- Mice MeSH
- Tumor Cells, Cultured MeSH
- Papillomaviridae * MeSH
- Cancer Vaccines administration & dosage MeSH
- Recombinant Proteins administration & dosage MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Adjuvants, Immunologic MeSH
- Interleukin-2 MeSH
- Cancer Vaccines MeSH
- Recombinant Proteins MeSH
Moderately immunogenic HPV 16-associated tumours TC-1 (MHC class I(+), HPV 16 E6/E7(+), G12V Ha-ras(+)) and MK16/1/III ABC (MHC class I(-), HPV 16 E6/E7(+), G12V Ha-ras(+)), both of the H-2(b) haplotype and transplanted in syngeneic mice, were used to examine the adjuvant effects of IL-2 and dendritic cells for surgical therapy. Mice were inoculated s.c. with the respective tumour cells, and when the tumours reached 8-12 mm in diameter, they were extirpated. Three days after surgery, the experimental mice were treated with IL-2, IL-2 gene-modified tumour vaccines, or dendritic cells, injected s.c. to the site of previous surgery. It has been found in both, MHC class I(+) and MHC class I(-) tumours that the recombinant IL-2 and IL-2 gene-modified vaccines substantially reduced the tumour recurrence rate and inhibited growth of tumour recurrences. The dendritic cells were significantly effective only in mice with surgical minimal residual TC-1 (MHC class I(+)) tumour disease and when injected before they have reached the terminal stage of their differentiation.
References provided by Crossref.org